Clinical trials: Nutritional Evaluation
Healthy
Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects
To assess the effect of PEX168 doses on the pharmacokinetics of digoxin in healthy subjects.To provide a scientific basis for clinical drug combination of PEX168.
- Trial name
- NCT02472236
- Testing
- PEX168, Digoxin
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus
Objectives: Primary Objectives To investigate the safety and tolerability of single ascending doses of AZP- 531 in healthy volunteers.
- Trial name
- NCT02040012
- Testing
- AZP-531
- Where
- United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Alizé Pharma
X-linked Hypophosphatemia (XLH)
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in pediatric Chinese patients with XLH
- Trial name
- NCT04842032
- Testing
- KRN23
- Where
- 5 sites in China
- Volunteers
- 28 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Type 1 Diabetes
To Evaluate the Bioavailability of a Tablet of AZD1656
To evaluate the bioavailability of a tablet of AZD1656.
- Trial name
- NCT00817505
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
Osteoporosis, Postmenopausal Osteoporosis
Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Alendronate (MK-0822-050)
This study will evaluate the therapeutic effects and safety of odanacatib on bone mineral density in osteoporotic postmenopausal women who were previously treated with alendronate.
- Trial name
- NCT01552122
- Testing
- Odanacatib, Alendronate, Cholecalciferol (Vitamin D3)
- Sponsor
- Merck Sharp & Dohme LLC
Hereditary Tyrosinemia, Type I
Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1
The purpose of this study is to look at the steady-state serum concentrations of nitisinone when switching from twice daily and once daily dosing.
- Trial name
- HT-1 (NCT02323529)
- Testing
- Nitisinone
- Where
- 6 sites in Belgium, Denmark and 3 more
- Volunteers
- 18 people
- Sponsor
- Swedish Orphan Biovitrum
Type 2 Diabetes Mellitus
Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)
GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823093, compared to placebo…
- Trial name
- NCT00387972
- Testing
- denagliptin (GW823093)
- Where
- 57 sites in United States
- Sponsor
- GlaxoSmithKline
Pre-diabetes
Evaluation of Video On-Demand Programming to Prevent Type 2 Diabetes in Adults
Over the past 40 years, diabetes has increased dramatically in parallel with rapid increases in obesity.About 90 to 95% of persons with diabetes have type 2 diabetes, which begins when the body becomes resistant to the hormone…
- Trial name
- Project NOT ME (NCT01768546)
- Testing
- Virtual Diabetes Prevention Program, Interactive tracking and problem solving web portal
- Volunteers
- 306 people
- Sponsor
- UnitedHealth Group
MPS IV A
A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
This Phase 3 study will evaluate the efficacy and safety of 2.0 mg/kg/week BMN 110 and 2.0 mg/kg/every other week BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).
- Trial name
- NCT01275066
- Testing
- BMN 110 Weekly, BMN 110 Every Other Week
- Where
- 28 sites in United States, Argentina and 15 more
- Volunteers
- 177 people
- Sponsor
- BioMarin Pharmaceutical
Dyslipidemia
Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin
The primary purpose of this study was to evaluate the psychometric characteristics (reliability, validity, and responsiveness) of a Flushing ASsessment Tool (FAST) in subjects receiving niacin extended-release (NER) plus aspirin…
- Trial name
- NCT00630877
- Testing
- Niacin extended-release (NER), Aspirin (ASA)
- Where
- 40 sites in United States
- Volunteers
- 276 people
- Sponsor
- Abbott
Gout
A Study of Dotinurad Versus Allopurinol in Participants With Gout
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
- Trial name
- NCT07089875
- Testing
- Allopurinol, Dotinurad
- Where
- 119 sites in United States, Poland and 1 more
- Volunteers
- 500 people
- Sponsor
- Crystalys Therapeutics
Type 2 Diabetes, Hypertension
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
[Primary Objective] To demonstrate the superiority of the change in mean sitting systolic blood pressure (MSSBP) and hemoglobin A1c (HbA1c)on week 12 of the combination therapy of THP-00101 (dapagliflozin 10 mg) and THP-00102…
- Trial name
- THP-001-031 (NCT06647745)
- Testing
- THP-00101, THP-00102, THP-00103
- Where
- 2 sites in South Korea, Thailand
- Volunteers
- 221 people
- Sponsor
- THPharm Corp.
Leber Hereditary Optic Neuropathy
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients
The purpose of this study is to evaluate the safety and tolerability profile of ascending doses of GS010 in Leber Hereditary Optic Neuropathy (LHON) patients.
- Trial name
- NCT02064569
- Testing
- GS010
- Where
- France
- Volunteers
- 19 people
- Sponsor
- GenSight Biologics
Diabetes Mellitus
A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China
The purpose of this study is to demonstrate the performance and safety of the Guardian™ Sensor (3) over 170 hours (7 days) when inserted in the abdomen used in subjects age 14 - 75 years with the Guardian™ Connect System.
- Trial name
- NCT03710083
- Testing
- Guardian™ Sensor (3)
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetic Gastroparesis
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered…
- Trial name
- DIGEST (NCT01664637)
- Testing
- 10 mg TZP-102
- Where
- 35 sites in United States, Poland
- Volunteers
- 120 people
- Sponsor
- Tranzyme, Inc.
Overweight/Obesity
Clinical Study of IBI362 in Healthy Chinese Male Subjects
This is a study to evaluate the pharmacokinetic characteristics and safety of IBI362 lyophilized powder and IBI362 liquid formulation in healthy Chinese male subjects.
- Trial name
- NCT04773977
- Testing
- IBI362 liquid formulation, IBI362 lyophilized powder
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
ASCVD, Elevated Cholesterol
Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol
This is a Phase III, placebo-controlled, double-blind, randomized study in participants with ASCVD and elevated LDL-C despite maximum tolerated dose of LDL-C lowering therapies to evaluate the efficacy, safety, and tolerability…
- Trial name
- ORION-10 (NCT03399370)
- Testing
- Inclisiran Sodium
- Where
- 145 sites in United States
- Volunteers
- 1,561 people
- Sponsor
- The Medicines Company
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Metabolic Syndrome, Impaired Glucose Tolerance
Evaluation of Low Source of Signal in SCOUT DS
The overall objective of this study is to increase the number of dark skin tone individuals in the data set and evaluate if this increase in dark skin tone data has an impact on the accuracy of the SCOUT DS Diabetes Risk Score…
- Conditions
- Metabolic Syndrome, Impaired Glucose Tolerance, Gestational Diabetes
- Trial name
- LSS (NCT01339637)
- Where
- 5 sites in United States
- Volunteers
- 196 people
- Sponsor
- VeraLight, Inc.
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease (ESRD) and cardiovascular deaths in patients with Stage 4 Chronic Kidney Disease (CKD) and type 2…
- Trial name
- BEACON (NCT01351675)
- Testing
- Bardoxolone Methyl: 20 mg
- Volunteers
- 2,185 people
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.